Pegaptanib Sodium
drugOn this page
Also known as EYE-001EYE001EYEOO1MacugenNX-1838NX1838Pegaptanib na
Summary
Pegaptanib Sodium (CHEMBL1201421) is an approved small molecule; indicated across 8 conditions including wet macular degeneration and age-related macular degeneration.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 8 conditions
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201421 |
| Name | Pegaptanib Sodium |
| Type | Small molecule |
| Max phase | 4 |
Also known as: EYE-001, EYE001, EYEOO1, Macugen, NX-1838, NX1838, Pegaptanib na, Pegaptanib sodium, PEGAPTANIB SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| wet macular degeneration | 4 | MONDO:0005417 | EFO:0004683 |
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| macular degeneration | 3 | MONDO:0003004 | EFO:0009606 |
| retinal vein occlusion | 2 | MONDO:0006951 | EFO:1001157 |
| choroidal neovascularization | 2 | MONDO:0810000 | MONDO:0810000 |
| von Hippel-Lindau disease | 1 | MONDO:0008667 | MONDO:0008667 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE3 | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00312351 | PHASE4 | TERMINATED | A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) |
| NCT00150202 | PHASE3 | COMPLETED | Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration) |
| NCT00321997 | PHASE2/PHASE3 | COMPLETED | A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD. |
| NCT00605280 | PHASE2/PHASE3 | COMPLETED | A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. |
| NCT01100307 | PHASE3 | COMPLETED | A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema |
| NCT01189461 | PHASE3 | COMPLETED | Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema |
| NCT01589718 | PHASE3 | WITHDRAWN | A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy |
| NCT00088283 | PHASE2 | COMPLETED | Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) |
| NCT00239928 | PHASE2 | COMPLETED | Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration |
| NCT00346983 | PHASE1/PHASE2 | TERMINATED | Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics |
| NCT00358423 | PHASE1/PHASE2 | TERMINATED | The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema |
| NCT00056199 | PHASE1 | COMPLETED | EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
| NCT06717035 | Not specified | NOT_YET_RECRUITING | Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children |
| NCT00088192 | Not specified | COMPLETED | Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| NCT00272766 | Not specified | TERMINATED | Macugen for Histoplasmosis |
| NCT00446381 | Not specified | COMPLETED | Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) |
| NCT00460408 | Not specified | COMPLETED | Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration |
| NCT00549055 | Not specified | COMPLETED | A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. |
| NCT00820742 | Not specified | WITHDRAWN | Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration. |
| NCT00845273 | Not specified | COMPLETED | Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration |
| NCT00858208 | Not specified | COMPLETED | Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).